8-K current report · filed Nov 18, 2026

Teva Pharmaceutical Industries Ltd (TEVA) 8-K Current Report: November 18, 2026

Item 5.02Item 7.01Item EX-99.1TEVA overview

Short answer

Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on November 18, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Dr. Eric Hughes resigning immediately as EVP, Global R&D and Chief Medical Officer.

Teva Pharmaceutical Industries Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Dr. Eric Hughes resigning immediately as EVP, Global R&D and Chief Medical Officer
  • Hughes remaining for several months to support transition
  • Immediate leadership gap in R&D and medical oversight, potentially affecting drug development execution and pipeline strategy

Item 7.01 · Regulation FD Disclosure

  • Dr. Eric Hughes will leave Teva, creating a senior leadership transition
  • Departure details and succession plans are contained in Exhibit 99.1
  • Investor focus: continuity of Teva’s strategic execution and medical leadership management

Item EX-99.1 · Exhibit EX-99.1

  • R&D chief Eric Hughes departing for an external role, creating near-term leadership transition risk
  • David Gardiner named interim R&D transition lead, reporting directly to CEO Richard Francis
  • Permanent successor search begins immediately, making execution during the transition a key investor focus
  • Teva reaffirmed its Pivot to Growth strategy and R&D priorities remain unchanged
  • Innovative medicines revenue ambition remains $6–7 billion by 2030

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Teva Pharmaceutical Industries Ltd 8-K filings

Get the next TEVA 8-K as it lands

Follow TEVA for push alerts, or ask the research agent what this filing means.